Nurix Therapeutics, Inc. (Nasdaq ... Strengthened balance sheet to support development of pipeline: Nurix ended its fiscal year with an estimated, unaudited $609.6 million in cash and investments ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

According to an Evotec statement, the initial collaboration has been "highly productive" in generating a pipeline of potential ... billion-plus deal with Lycia Therapeutics spanning up to five ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Nurix Therapeutics has a fifty-two week low of $8.11 and a fifty-two week high of $29.56. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -6.53 and a beta of 2.14.

Kate Therapeutics' pipeline is still in the preclinical stage of development but includes candidates for DMD, facioscapulohumeral dystrophy (FSHD), and myotonic dystrophy type 1 (DM1), as well as ...

Andy Smith is a Certified Financial Planner (CFP®), licensed realtor and educator with over 35 years of diverse financial management experience. He is an expert on personal finance, corporate ...